New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
10:00 EDTKWK, AGN, SD, DGI, BIG, UNFI, MCY, GRP, DDAIF, AWK, CWH, SCTY, VITC, FMS, DVAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Water (AWK) downgraded to Neutral from Buy at Citigroup... Big Lots (BIG) downgraded to Hold from Buy at Canaccord... DaVita (DVA) downgraded to Hold from Buy at Deutsche Bank... Daimler AG (DDAIF) downgraded to Neutral from Buy at Citigroup... DigitalGlobe (DGI) downgraded to Hold from Buy at Benchmark Co... Fresenius Medical (FMS) downgraded to Sector Perform from Outperform at RBC Capital... Granite Real Estate (GRP) downgraded to Sector Perform from Outperform at RBC Capital... Lincoln Educational (LINC) downgraded to Underperform from Market Perform at BMO Capital... SandRidge Energy (SD) downgraded to Underperform from Market Perform at BMO Capital... Vitacost.com (VITC) downgraded to Sell from Neutral at Roth Capital... Mercury General (MCY) downgraded to Neutral from Outperform at Macquarie... Allergan (AGN) downgraded to Neutral from Buy at Buckingham... SolarCity (SCTY) downgraded to Hold from Buy at Needham... United Natural Foods (UNFI) downgraded to Hold from Buy at Argus... Quicksilver Resources (KWK) downgraded to Hold from Buy at MLV Equity... CommonWealth REIT (CWH) downgraded to Sell from Hold at Stifel Nicolaus.
News For AWK;BIG;DVA;DDAIF;DGI;FMS;GRP;SD;VITC;MCY;AGN;SCTY;UNFI;KWK;CWH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 19, 2015
07:06 EDTFMSFresenius Medical reports data on DHR pilot, plans expansion
Subscribe for More Information
06:37 EDTSCTYSolarCity Q4 results show 'robust' demand environment, says Deutsche Bank
Subscribe for More Information
04:46 EDTSDStocks with implied volatility movement; GDP SD
Subscribe for More Information
February 18, 2015
18:55 EDTSCTYOn The Fly: After Hours Movers
Subscribe for More Information
18:22 EDTSCTYSolar stocks struggle in extended session after SolarCity results
Solar stocks are trading down in the extended session after SolarCity (SCTY) reported a larger fourth quarter loss than expected and guided to a first quarter loss well below consensus estimates. WHAT'S NEW: Solar city said adjusted non-GAAP earnings per share for Q4 was a loss of ($1.33) against estimates of a loss of ($1.27). Revenue for the quarter was in-line at $71.8M. The company also guided for a loss of ($1.75)-($1.65) per share in the current quarter which is below analysts' average estimates for a loss of ($1.25) per share. However, the company did note, " With end-market demand healthy and growing, our installation capacity steadily ramping and a majority of our financing needs secured for the year, we remain confident in achieving our guidance to deploy 920-1000MW in 2015." PRICE ACTION: Shares of SolarCity are down over 5% to $54.01 in the after-hours session. OTHERS TO WATCH: Other stocks in the solar space trading lower in the extended session include SunPower (SPWR), SunEdison (SUNE), Vivint Solar (VSLR), and First Solar (FSLR).
18:11 EDTSCTYSolarCity reports Q4 adjusted non-GAAP EPS ($1.33), consensus ($1.27)
Subscribe for More Information
16:46 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
16:32 EDTSCTYSolarCity drops 5% to $54.31 following Q4 results
16:31 EDTSCTYSolarCity says majority of financing secured for 2015 needs
SolarCity said, "Following strong growth in 2014, we entered 2015 with high visibility into our full year guidance for 920 - 1,000 MW Deployed. After booking almost 300 MW more than we deployed in 2014, we began the year with a backlog big enough to cover much of our expected first half installations. Ending the year with residential deployments at an annualized run rate of ~600 MW, we have significantly ramped up our installation capacity and plan to scale this beyond 1 GW by year-end even before considering commercial. Lastly, we have secured a majority of the financing commitments required to fund all of our 2015 needs."
16:17 EDTSCTYSolarCity sees Q1 EPS ($1.75)-($1.65), consensus ($1.25)
Subscribe for More Information
16:00 EDTSCTYOptions Update; February 18, 2015
Subscribe for More Information
15:35 EDTSCTYNotable companies reporting after market close
Subscribe for More Information
14:54 EDTSCTYSolarCity technical notes before earnings news
Shares have been trading in a range bound largely by $47 at the low and $59 at the high for the last several months. A break of either end of this range following results will resolve the range either bearishly or bullishly. If the news is bullish and there is a breakout above $59, next resistance is at $63.30 and then at $65.60. If the news disappoints, first major support below would be at the 50-day moving average at $52.53. It would take exceptionally bearish news to push the shares to the range low. The low of the range was also previously support in the early part of last year. The 52-week low is at $45.79.
12:31 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
11:14 EDTSCTYSolarCity volatility increases into Q4 and outlook
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
09:14 EDTUNFIAmira Nature Foods partners with United Natural Foods, Crossmark
Subscribe for More Information
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use